RICCI, Giovanni
RICCI, Giovanni
DIPARTIMENTO DI MEDICINA INTERNA E SPECIALITA' MEDICHE (attivo dal 01/07/2010 al 31/10/2019)
A randomized controlled trial on pegylated interferon alfa-2a (40 KD, Pegasys®) or IFN alfa-2a (Roferon-A) plus ribavirin (RBV) and amantadine (AMA) vs IFN alfa-2a and RBV in naïve patients with chronic HCV.
2005 A., Mangia; Ricci, Giovanni; N., Minerva; M., Persico; V., Carretta; D., Bacca; M., Cela
Acute and long-term effects of inhaled iloprost in portopulmonary hypertension
2010 M. T., Melgosa; Ricci, Giovanni; J. C., GARCÍA PAGAN; I., Blanco; P., Escribano; J. G., Abraldes; J., Roca; J. BOSCH, J. A. BARBERÀ
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection
2009 Mangia, A; Minerva, N; Bacca, D; Cozzolongo, R; Agostinacchio, E; Sogari, F; Scotto, G; Vinelli, F; Ricci, Giovanni; Romano, M; Carretta, V; Petruzzellis, D; Andriulli, A.
Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial
2008 Mangia, A; Minerva, N; Bacca, D; Cozzolongo, R; Ricci, Giovanni; Carretta, V; Vinelli, F; Scotto, G; Montalto, G; Romano, M; Cristofaro, G; Mottola, L; Spirito, F; Andriulli, A.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A randomized controlled trial on pegylated interferon alfa-2a (40 KD, Pegasys®) or IFN alfa-2a (Roferon-A) plus ribavirin (RBV) and amantadine (AMA) vs IFN alfa-2a and RBV in naïve patients with chronic HCV. | 2005 | A., Mangia; Ricci, Giovanni; N., Minerva; M., Persico; V., Carretta; D., Bacca; M., Cela | |
| Acute and long-term effects of inhaled iloprost in portopulmonary hypertension | 2010 | M. T., Melgosa; Ricci, Giovanni; J. C., GARCÍA PAGAN; I., Blanco; P., Escribano; J. G., Abraldes; J., Roca; J. BOSCH, J. A. BARBERÀ | |
| Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection | 2009 | Mangia, A; Minerva, N; Bacca, D; Cozzolongo, R; Agostinacchio, E; Sogari, F; Scotto, G; Vinelli, F; Ricci, Giovanni; Romano, M; Carretta, V; Petruzzellis, D; Andriulli, A. | |
| Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial | 2008 | Mangia, A; Minerva, N; Bacca, D; Cozzolongo, R; Ricci, Giovanni; Carretta, V; Vinelli, F; Scotto, G; Montalto, G; Romano, M; Cristofaro, G; Mottola, L; Spirito, F; Andriulli, A. |